Novocure Partners With Verastem Oncology on Pancreatic Cancer Trial

By Public Technologies
  • Novocure entered a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate a combination treatment for locally advanced pancreatic cancer.
  • The trial will combine Tumor Treating Fields therapy with chemotherapy and VS-7375, Verastem's investigational oral KRAS G12D inhibitor.
  • Enrollment is expected to begin in 2027, targeting approximately 25 patients.
  • Researchers will assess safety and tolerability, with preliminary efficacy evaluated as exploratory endpoints.
  • Under the agreement, Novocure will manage and fund trial operations; Verastem will supply VS-7375.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610280700BIZWIRE_USPR_____20261028_BW077167) on October 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk